Seegene Unveils Revolutionary Unattended PCR Automation System at ADLM 2025

Seegene's Revolutionary Step in Diagnostics: CURECA™ and STAgora™

Seegene Inc., a global leader in molecular diagnostics, has made a monumental announcement today. The company will unveil its fully automated PCR system, named CURECA™, at the prestigious ADLM 2025 (Association for Diagnostics Laboratory Medicine) conference in Chicago, scheduled from July 28 to 31, 2025. This innovative technology is expected to transform the landscape of diagnostic testing, making significant strides towards a more efficient and reliable process.

What is CURECA™?

CURECA™ stands as the world's first entirely automated PCR testing system. It manages every element of the PCR testing process autonomously—from sample preservation and pretreatment to nucleic acid extraction, amplification, and result analysis—without requiring any human intervention. Designed for continuous operation, the system functions 24/7 to minimize errors and enhance the consistency and reliability of test results.

A distinctive feature of CURECA™ is its fully automated pretreatment module, which tackles one of the most labor-intensive and error-prone stages in laboratory workflows. Traditionally, the pretreatment phase presents significant challenges, especially when handling diverse sample types like urine, blood, sputum, and feces. In many labs, technicians often perform repetitive manual tasks that can lead to inconsistent results due to varying skill levels.

Notably, fecal samples have historically posed a serious challenge for automation, given their high viscosity and complex particulate composition, necessitating careful manual handling. CURECA™ has overcome these hurdles by fully automating the pretreatment process for all major sample types, including feces. This breakthrough reduces the reliance on manual labor, increases sample processing speeds, improves operational efficiency, and significantly lowers costs. As a result, laboratory personnel can shift their focus from routine processing to higher-level responsibilities, such as data analysis and clinical interpretation.

Further Applications of CURECA™

Beyond PCR diagnostics, the pretreatment module of CURECA™ also supports other disciplines like clinical chemistry and immunoassays, illustrating a major advancement in automation within the broader diagnostics market. Its modular architecture allows for flexible configurations and implementations tailored to the specific size, layout, and needs of any laboratory.

Introducing STAgora™ – Real-Time Global Data Integration

Alongside CURECA™, Seegene will also showcase STAgora™, a powerful statistical platform that aggregates and analyzes PCR diagnostic data in real-time. This software enables clinical decision-making processes by compiling test data from hospitals worldwide. STAgora™ provides integrated information about regional infection trends, hospital positivity rates, and co-infection patterns, along with access to over 40 statistical tools designed to support clinical operations.

With the aid of STAgora™, healthcare providers can compare individual patient test results against local and regional epidemiological data, allowing for more precise and data-driven treatment strategies. This platform empowers physicians to assess infection trends on both patient and community levels, thereby enhancing the accuracy and speed of diagnosis and patient care planning.

Expanding Global Collaboration through Technological Partnerships

In light of its upcoming presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by facilitating pilot experiences and forging new global partnerships. Earlier this year, CURECA™ garnered substantial interest at the ESCMID Global 2025, one of Europe’s leading conferences on clinical microbiology and infectious diseases. To strengthen its R&D and manufacturing capabilities in the United States, Seegene has established local affiliates, including Seegene Technologies and Seegene CURECA.

Daniel Shin, Executive Vice President and Global Sales and Marketing Director at Seegene, highlighted, "CURECA™ and STAgora™ are more than mere diagnostic tools; they represent a new global standard that will redefine diagnostics across clinical environments worldwide. We will continue to share the numerous technological resources we have developed over the years, driving fundamental innovation across the global diagnostic ecosystem."

Acknowledgment of Precommercialization

It's important to note that CURECA™ and STAgora™ are currently in a precommercialization phase. The configurations presented at ADLM 2025 are purely for demonstration purposes and may differ from the final commercial versions in terms of functionalities, specifications, and components. This material serves solely to showcase the technology and does not constitute an advertisement for the product's sale.

About Seegene

With over 20 years of dedicated experience in R&D, production, and related commercial activities in syndromic real-time PCR technologies, Seegene's expertise shone brightly during the COVID-19 pandemic when the company delivered more than 340 million COVID-19 tests across over 100 countries. Seegene’s syndromic PCR technology allows for the simultaneous detection of 14 pathogens causing similar clinical signs and symptoms in a single reaction tube, providing quantitative insight for each pathogen.

For more information, visit Seegene's website and follow the company on LinkedIn.